000142473 001__ 142473
000142473 005__ 20240229105148.0
000142473 0247_ $$2doi$$a10.1016/j.ccell.2018.11.013
000142473 0247_ $$2pmid$$apmid:30537508
000142473 0247_ $$2ISSN$$a1535-6108
000142473 0247_ $$2ISSN$$a1878-3686
000142473 0247_ $$2altmetric$$aaltmetric:52670801
000142473 037__ $$aDKFZ-2019-00192
000142473 041__ $$aeng
000142473 082__ $$a610
000142473 1001_ $$0P:(DE-He78)c403a040c97f91902a7d31b93859f9fc$$aLipka, Daniel$$b0$$eFirst author$$udkfz
000142473 245__ $$aFrom Basic Knowledge to Effective Therapies.
000142473 260__ $$aNew York, NY$$bElsevier$$c2018
000142473 3367_ $$2DRIVER$$aarticle
000142473 3367_ $$2DataCite$$aOutput Types/Journal article
000142473 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1550145185_26422
000142473 3367_ $$2BibTeX$$aARTICLE
000142473 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000142473 3367_ $$00$$2EndNote$$aJournal Article
000142473 520__ $$aIn this issue of Cancer Cell, Ott et al. use integrative analysis of histone ChIP-seq and ATAC-seq to describe enhancer-based regulatory circuits in chronic lymphocytic leukemia. This work identified and validated transcription factor PAX5 as main driver of an oncogenic circuitry, which can be disrupted by BET bromodomain inhibition.
000142473 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000142473 588__ $$aDataset connected to CrossRef, PubMed,
000142473 7001_ $$0P:(DE-He78)ff1677c63392be9b31a1c8d23db7c9dc$$aLutsik, Pavlo$$b1$$udkfz
000142473 7001_ $$0P:(DE-He78)4301875630bc997edf491c694ae1f8a9$$aPlass, Christoph$$b2$$eLast author$$udkfz
000142473 773__ $$0PERI:(DE-600)2074034-7$$a10.1016/j.ccell.2018.11.013$$gVol. 34, no. 6, p. 871 - 873$$n6$$p871 - 873$$tCancer cell$$v34$$x1535-6108$$y2018
000142473 909CO $$ooai:inrepo02.dkfz.de:142473$$pVDB
000142473 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c403a040c97f91902a7d31b93859f9fc$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000142473 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ff1677c63392be9b31a1c8d23db7c9dc$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000142473 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4301875630bc997edf491c694ae1f8a9$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000142473 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000142473 9141_ $$y2018
000142473 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCER CELL : 2017
000142473 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000142473 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000142473 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000142473 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000142473 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000142473 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000142473 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000142473 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000142473 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000142473 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000142473 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000142473 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000142473 915__ $$0StatID:(DE-HGF)9920$$2StatID$$aIF >= 20$$bCANCER CELL : 2017
000142473 9201_ $$0I:(DE-He78)C010-20160331$$kC010$$lEpigenomik und Krebsrisikofaktoren$$x0
000142473 980__ $$ajournal
000142473 980__ $$aVDB
000142473 980__ $$aI:(DE-He78)C010-20160331
000142473 980__ $$aUNRESTRICTED